Date: September 16, 2011
Company: Emergent BioSolutions, Lansing, MI
Contract amount: One year at $500,000 with options to extend the contract (based on meeting performance milestones) for a total of up to three years and up to $2.7 million
About the contract: Emergent BioSolutions will evaluate the stability of bulk filtrate of its FDA-licensed anthrax vaccine, BioThrax, and the BioThrax-enhancement candidate, AV7909, when stored at negative 70 degrees Celsius.
Additional information: The contract was funded through the BARDA Broad Agency Announcement (BAA) (CBRN-BAA-09-34) and falls under the Biodefense Medical Countermeasures Development Fund (BMCDF) established by the Pandemic and All-Hazards Preparedness Act of 2006. The BMCDF is used to support the development of technologies that the federal government needs for emergency preparedness. Products that mature under this program may later be considered for purchased through the Project BioShield Special Reserve Fund. BARDA is seeking additional proposals for vaccines could potentially prevent anthrax disease. Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at www.fbo.gov.
